Biolase has obtained rights to market its new diode laser technology in the US and throughout the European Union (EU) and in those Asian and Latin American countries that recognize the CE mark.
The EPIC 10 diode soft tissue laser utilizes the company’s proprietary ComfortPulse technology to allow dentists to precisely control the level of laser energy that penetrates the target tissue.
The technology also keeps patients more comfortable by avoiding pain-inducing heat buildup at the surgical site, which can also cause excessive tissue damage.
Biolase chief technology officer Dmitri Boutoussov said the next generation diode soft tissue laser allows for cleaner cutting, superior hemostasis, improved patient comfort, and greater versatility.
"Further, the EPIC 10 features a revolutionary and intuitive applications-based user interface with a high-resolution touch screen pre-programmed with 15 of the most commonly performed soft tissue procedures, including Pain Therapy, which is a highly popular treatment in the dental community for addressing pain in the oral-maxillofacial region," Boutoussov added.
Biolase chairman and chief executive officer Federico Pignatelli said the company is pleased to have received FDA clearance and the CE Mark for the new diode laser technology platform.
"While the EPIC 10 became available to sell in a limited number of countries internationally only in the final days of the third quarter of 2012, BIOLASE enjoyed solid year over year and sequential growth in its core Waterlase products, enabling the Company to meet its previously stated financial guidance for the quarter," Pignatelli added.
"We are very pleased with the backlog we have generated internationally for the EPIC 10, as well as very strong domestic interest.
"We expect the EPIC 10 to make significant contributions to our revenue in the 2012 fourth quarter and beyond."